Sir,
The recent review article by Kneeshaw et al (2003) in the British Journal of Cancer regarding advances made in breast imaging by magnetic resonance is very encouraging and its expedited entry into routine clinical practice should be supported. This is not only due to its anticipated enhanced sensitivity and usefulness, but potentially also for its safety, particularly as may apply to radiation hypersensitivities such as female carriers of ataxia telangiectasia (AT).
Ataxia telangiectasia is a genetic cancer predisposition syndrome involving the overexpression of alpha-fetoprotein, immunosuppression of the host, advanced ageing, and a radiation hypersensitivity where AT homozygotes generally succumb to infection or to lymphoma before reaching adulthood (reviewed in Becker-Catania and Gatti, 2001). Female AT heterozygotes are at an increased risk of breast cancer, but this is usually detected after the age of 40 years (Swift et al, 1991; Swift, 2001,). The issue of safety of ionising radiation used for breast cancer screening has been previously raised for AT heterozygotes (Swift et al, 1991). About 1% of the population carries the genetic marker for AT, and 8–10% of all breast cancers appear to be AT heterozygotes (reviewed in Swift, 2001). This indicates the use of nonionising modes of breast imaging could make a significant impact on the incidence of breast cancers. However, other evidence suggests these potential benefits might also be extended into the general female population.
A number of years ago while investigating the molecular biology of the AT radiation hypersensitivity, it was discovered that radioresistant DNA synthesis (RDS), the molecular signature of the radiation hypersensitivity of AT, could be modulated (Mirzayans et al, 1995; Mirzayans and Paterson, 2001). When c-myc and alpha-fetoprotein became implicated in the RDS phenotype (Laderoute, unpublished findings), oestrogen was tested for its ability to induce RDS in cells derived from normal individuals. As shown in Figure 1, RDS was induced by estradiol (E2) but not progesterone in a dose-responsive fashion in lymphoblastoid cell lines (LCLs) derived from normal individuals (panel A). The induction was specific to oestrogen as it was blocked in the presence of an excess of tamoxifen (panel C), an oestrogen antagonist (Laderoute, 1998). Furthermore, additional experiments showed the RDS assay could be geared to easily detect low dose ionising radiation exposures around 1 rad or less in radiation hypersensitive cells such as those from AT individuals or AT heterozygotes (Laderoute, 1998). These results raised the possibility that breast imaging techniques using low-dose ionising radiation may induce breast cancers or cause existing breast tumours to progress, if the circulating levels of oestrogen are elevated in women at the time of mammography exposure. This phenomenon might help explain the reduced benefits in the under 50 years age-at-entry group reported in mammogram clinical trials (Miller et al, 1992, 2002), the increased incidence of breast cancer with mammogram screening among 45- to 64- year olds not accountable by earlier detection (White et al, 1990), and the lack of impact of mammography screening for reducing breast-cancer mortality overall (Gotzsche and Olsen, 2000).
It remains to be seen if the incidence of breast cancer returns to the premammogram screening rates of the 1960 s and 1970 s, as ionising radiation-based breast imaging technologies are replaced by MR imaging and as women decline hormone replacement therapies. One might also expect survival to again correlate inversely with tumour size, which is why early breast cancer imaging methods were introduced in the first place.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Becker-Catania SG, Gatti RA (2001) Ataxia-telangiectasia. Adv Exp Med Biol 495: 191–198
Gotzsche PC, Olsen O (2000) Is screening for breast cancer with mammography justifiable? Lancet 355: 129–134
Kneeshaw PJ, Turnbull LW, Drew PJ (2003) Current applications and future direction of MR mammography. Bri J Cancer 88: 4–10, doi10.1038/sj.bjc.6600713
Laderoute MP (1996) Alterations in p53 do not correlate with radioresistant DNA synthesis. Anticancer Res 16: 2825–2830
Laderoute MP (1998) Adverse low dose ionizing radiation effects (negative hormesis) in ataxia telangiectasia (AT) cells and estrogen treated cells from normal individuals. In Proceedings of the International Symposium of Health Effects of Low Doses of Ionizing Radiation: Research Directions into the New Millennium, Elaguppillai EV, Duport PJ (eds) pp 206–214. Ottawa: University of Ottawa Press
Miller AB, Baines CJ, To T, Wall C (1992) Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 147: 1459–1476
Miller AB, To T, Baines CJ, Wall C (2002) The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women aged 40 to 49 years. Ann Intern Med 137: 305–312
Mirzayans R, Famulski KS, Enns L, Fraser M, Paterson MC (1995) Characterization of the signal transduction pathway mediating gamma ray-induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53. Oncogene 11: 1597–1605
Mirzayans R, Paterson MC (2001) Correction of radioresistant DNA synthesis in ataxia telangiectasia fibroblasts by prostaglandin E2 treatment. Environ Mol Mutagen 38: 191–199
Swift M (2001) Public health burden of cancer in ataxia-telangiectasia heterozygotes. J Natl Cancer Inst 93: 84–85
Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831–1836
White E, Lee CY, Dristal AR (1990) Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst 82: 1546–1552
Author information
Authors and Affiliations
Corresponding author
Additional information
The views expressed in this letter are those of the author based on work previously performed at the Cross Cancer Institute, Edmonton, Alberta in the Department of Molecular Carcinogenesis and do not necessarily reflect the official opinions of Health Canada.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Laderoute, M. Improved safety and effectiveness of imaging predicted for MR mammography. Br J Cancer 90, 278–279 (2004). https://doi.org/10.1038/sj.bjc.6601442
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601442
This article is cited by
-
Exact quantification of time signals from magnetic resonance spectroscopy by the fast Padé transform with applications to breast cancer diagnostics
Journal of Mathematical Chemistry (2009)
-
Mathematical Optimization of in vivo NMR Chemistry Through the Fast Padé Transform: Potential Relevance for Early Breast Cancer Detection by Magnetic Resonance Spectroscopy
Journal of Mathematical Chemistry (2006)